Search results
Results From The WOW.Com Content Network
OPK earnings call for the period ending September 30, 2024.
Latest approval for OPKO's (OPK) NGENLA is expected to reduce the treatment frequency from daily injections, thereby better serving the GHD patient pool.
Opko Health announced the initiation of a Phase 2 trial of Rayaldee as a treatment for mild-to-moderate COVID-19. After rising in the pre-market trading hours, Opko stock was down 0.63% at the ...
Image source: The Motley Fool. Opko Health (NASDAQ: OPK) Q2 2024 Earnings Call Aug 07, 2024, 4:30 p.m. ET. Contents: Prepared Remarks. Questions and Answers. Call ...
OPKO Health's (OPK) first-quarter results benefit from increase in RAYALDEE prescriptions. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 more ways ...
OPKO Health is a diversified healthcare company present in more than 30 countries. The company's primary businesses include [citation needed] Bioreference Laboratories, a clinical laboratory with a core genetic testing business; The 4K Test Score, a blood test for prostate cancer; Pharmaceutical development, with products such as Rayaldee
OPKO Health (OPK) delivered earnings and revenue surprises of -100% and 3.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
The HDP-2200 Future Offshore Patrol Vessel is a class of six (6) offshore patrol vessels designed and built by Hyundai Heavy Industries (HHI) for the Philippine Navy.. The Philippine Navy is expecting the delivery of six new offshore patrol vessels acquired under its Offshore Patrol Vessel Acquisition Project under the Revised AFP Modernization Program's Horizon 2 phase covering years 2018 to ...